Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc. is a scientific leader in skincare, dedicated to the development and commercialization of products addressing common and underserved skin conditions. The Company was initially founded to research and develop prescription products. Its lead asset, XYNGARI (also known as DMT310), was studied in clinical trials for moderate-to-severe acne. In March 2025, Dermata announced statistically significant results from its Phase 3 STAR-1 clinical trial of XYNGARI, which demonstrated statistically significant results across all three co-primary endpoints at weeks 4, 8, and 12 when compared with placebo. Following this trial, in September 2025, management, with board support, shifted strategy to developing and distributing direct-to-consumer (DTC) and business-to-business (B2B) skincare products. This strategic repositioning aims to accelerate commercialization, reduce regulatory burden, and decrease development expenses by leveraging the Company's dermatology knowledge to create effective and safe skincare products available without a prescription.